Beta Launch Saturday, 18 August 2018
Global Dow 3.79
2,835.68 0.13%
27 August 08:59 PM
S&P 500 4.08
2,443.05 0.17%
25 August 05:03 PM
EGX 23.25
12,949.65 0.18%
27 August 12:00 AM
TDWL -20.48
7,225.18 -0.28%
27 August 12:00 AM
DFM -21.94
3,602.55 -0.61%
27 August 12:00 AM
ADX -13.82
4,479.99 -0.31%
27 August 12:00 AM

World Hepatitis Day on July 28

World Hepatitis Day (WHD) takes places every year on July 28 bringing the world together under a single theme to raise awareness of the global burden of viral hepatitis and to influence real change.The theme for World Hepatitis Day 2018 is “Eliminate Hepatitis.”

World Hepatitis Day (WHD) takes places every year on 28 July bringing the world together under a single theme to raise awareness of the global burden of viral hepatitis and to influence real change.

Worldwide, 300 million people are living with viral hepatitis unaware. Without finding the undiagnosed and linking them to care, millions will continue to suffer, and lives will be lost.

On World Hepatitis Day, 28 July, a call will be released to urge people from across the world to take action, raise awareness and join in the quest to find the “missing millions”.

 Hepatitis B virus (HBV) takes a huge human and economic toll. Despite this, research into HBV is drastically underfunded, to the point that it was recently compared to a neglected tropical disease. But hope for a cure is growing.

Causing more than 887 000 deaths each year, HBV is a major threat to global public health. Some 257 million people worldwide are chronically infected with HBV, and the disease causes around 40% of all primary liver cancers – the second most deadly cancer.

In 2016, global partners joined forces to create the International Coalition to Eliminate Hepatitis B (ICE-HBV), with the aim of fast-tracking the discovery of a cure for HBV. The ICE-HBV formed international working groups comprising more than 50 global scientific leaders in HBV virology, immunology, technology and clinical research. The fruits of this partnership are now starting to show.

At the International Liver Congress (ILC) in Paris in April 2018, ICE-HBV members reported on encouraging developments towards an HBV cure. There are now almost 50 new anti-HBV and hepatitis D virus treatments being openly investigated, and 17 of these are already undergoing phase II clinical trials.

While a vaccine to prevent HBV exists, lifelong treatment is needed for those already chronically infected. Treatment helps keep HBV under control, but it is not a cure because it cannot completely clear HBV from infected cells. In addition, even with ongoing treatment, people are still at a higher risk of developing liver cancer, particularly those with underlying cirrhosis due to chronic HBV.

Recent scientific progress – and the momentum created by the discovery of a cure for hepatitis C virus (HCV) – has created a sense of renewed hope, as well as increased pressure, to find a cure for HBV, which affects more people and has a higher death rate than HCV.

Pre-clinical studies in animals also presented at ILC 2018 revealed that the most promising strategies are based on a combination of antiviral approaches that target both the virus itself (direct acting) and the human cells that host the virus (indirect acting). Indeed, getting HBV to stop replicating seems necessary, but it isn’t enough to stop the virus returning after treatment is discontinued.

In mice, effective new direct antivirals targeting the virus, combined with a therapeutic vaccination that aims to eliminate the virus, followed by immune boosting, gave promising results towards achieving a HBV “functional cure” – i.e. where HBV is reduced to permanently harmless levels after stopping treatment, but some residual virus may still be present in the body.

However, none of the approaches have so far had an effect on reaching the viral reservoir in the liver – this remains a major objective for future strategies.

While it is not possible to give a precise timeline, hope of finding an HBV cure is strong, and the scientific community – academic and industry alike – are clearly racing in the right direction.

 

RECOMMENDED

COMMENTS

There are no comments yet

LEAVE A COMMENT

Share with

My Account

Forgot password?

Create An Account

Forgot password?

Restore password

Subscribe to read
Already subscribed? Click here

For a limited time!
12 Months = 15 Months
24 Months = 32 Months
(Included Postal Fees worldwide)

Read, Explore Opportunities
Be connected with Business, Investment, Finance, Stock Exchange, Currencies, Development and International Cooperation

3 Months

18 USD / 60 AED

English Edition

Subscribe

3 Months

18 USD / 60 AED

Arabic Edition

Subscribe

3 Months

29.9 USD / 99 AED

Both Editions

Subscribe

6 Months

36 USD / 120 AED

English Edition

Subscribe

6 Months

36 USD / 120 AED

Arabic Edition

Subscribe

6 Months

59.9 USD / 199 AED

Both Editions

Subscribe

12 Months

72 USD / 240 AED

English Edition
Good Deal! 
(15 Months instead of 12 Months)

Subscribe

12 Months

72 USD / 240 AED

Arabic Edition
Good Deal! 
(15 Months instead of 12 Months)

Subscribe

12 Months

122 USD / 408 AED

Both Editions
Good Deal! 
(15 Months instead of 12 Months)

Subscribe

24 Months

144 USD / 480 AED

English Edition
Amazing Deal!
(32 Months instead of 24 Months)

Subscribe

24 Months

144 USD / 480 AED

Arabic Edition
Amazing deal!
(32 Months instead of 24 Months)

Subscribe

24 Months

240 USD / 799 AED

Both Editions
Amazing deal!
(32 Months instead of 24 Months)

Subscribe
* Terms and conditions apply.